胸腺法新对紫杉醇、顺铂联合方案治疗中晚期食管癌增效减毒作用研究

Study on the Synergistic and Attenuating Effects of Thymalfasin on Paclitaxel Combined with Cisplatin Regimen in the Treatment of Advanced Esophageal Cancer

目的 探究胸腺法新对紫杉醇联合顺铂(TP)方案治疗中晚期食管癌的增效减毒作用。方法 选取2021年6月—2023年6月收治的中晚期食管癌120例,随机分为观察组和对照组,各60例。对照组行TP方案治疗,观察组行胸腺法新联合TP方案治疗。比较2组疗效、生活质量改善率、毒副反应、1年生存率及T淋巴细胞亚群、癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)水平。结果 观察组客观缓解率、生活质量改善率及1年生存率高于对照组,恶心呕吐、骨髓抑制发生率低于对照组(P<0.05);治疗1、4个疗程,观察组CD8+、CD4+、CD3+、CD4+/CD8+较对照组改善幅度大(P<0.05);2组治疗1、4个疗程血清CEA、SCC-Ag及CA19-9水平均较治疗前下降,且观察组较对照组低(P<0.05)。结论 胸腺法新可通过增强机体免疫功能对TP方案治疗中晚期食管癌发挥增效减毒作用。

Objective To explore the synergistic and attenuating effects of Thymalfasin on paclitaxel combined with cisplatin(TP) regimen in the treatment of advanced esophageal cancer.Methods A total of 120 patients with moderate and advanced esophageal cancer treated from June 2021 to June 2023 were randomly divided into observation group(n=60) and control group(n=60).The control group was treated with TP regimen,and the observation group was treated with Thymalfasin combined with TP regimen.The efficacy,improvement rate of quality of life,toxicity,1-year survival rate and the levels of T lymphocyte subsets,carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag) and carbohydrate antigen 19-9(CA19-9) before and after treatment were compared between the two groups.Results The objective remission rate,improvement rate of quality of life and 1-year survival rate in observation group were higher than those in control group,while the incidence of nausea,vomiting and myelosuppression was lower than that in control group(P<0.05).After 1 and 4 courses of treatment,CD8+,CD4+,CD3+,and CD4+/CD8+ in the observation group had a higher improvement than that in the control group(P<0.05).Serum CEA,SCC-Ag and CA19-9 levels in the two groups after 1 and 4 courses of treatment were lower than those before treatment,and lower in the observation group than in the control group(P<0.05).Conclusion Thymalfasin can enhance the immune function of the body and play a synergistic and attenuating role in the treatment of advanced esophageal cancer by TP regimen.